Navigation Links
Common autism supplement affects endocrine system
Date:7/15/2013

Plant-based diets are healthy. Plants are high in flavonoids. So flavonoids are healthy. At least that's the reasoning of many manufacturers of flavonoid-based nutritional supplements. But a University of Colorado Cancer Center study published this week in the journal Hormones & Cancer shows that may not be the case. Flavonoids tested in the study affected the endocrine system in ways that in one case promoted cancer and in another repressed it.

"Even outside these specific findings with cancer, what we're saying is that flavonoids are active and not always in good or even predictable ways," says Steven K. Nordeen, PhD, investigator at the CU Cancer Center and professor emeritus in the Department of Pathology at the CU School of Medicine.

His study explored the effects of the flavonoids luteolin and quercetin on cell models of breast and endometrial cancer. In over-the-counter supplement form, the first compound, luteolin, is commonly recommended for the treatment of pediatric autism spectrum disorders.

Nordeen and colleagues show that luteolin blocks some of the endocrine effects of the hormone progesterone. Work from another CU Cancer Center investigator, Carol Sartorius, PhD, had previously shown that progesterone expands a population of therapy-resistant, stem cell-like cells in some breast cancers. In the present work, Nordeen showed that luteolin blocked this increase a beneficial effect. But then in an endometrial cancer cell model, luteolin had two deleterious effects. First, it acted like estrogen to directly stimulate cancer cell growth and second, by again blocking progesterone's action, luteolin disabled the brake that progesterone puts on estrogen-dependent endometrial cancer growth.

What helps in breast cancer hurts in endometrial cancer. But Nordeen says the most important issue is the simple fact that these flavonoids are active and we don't yet know how the body responds to the blood levels of flavonoids reached when taking supplements.

In the case of luteolin supplements for autism/spectrum, "You're giving prepubescent kids a supplement that affects the endocrine system and that's dangerous," Nordeen says.

He points out that "nutraceuticals" which include flavonoid and other active-ingredient supplements aren't FDA regulated to the degree that are medicines. This allows manufacturers to market supplements without fully testing nutraceutical products for efficacy or potential side effects.

"I'm not saying that flavonoids in a normal, plant-rich diet are bad," Nordeen says, "but caution is warranted when consuming additional flavonoids via supplements.

Detrimental effects of flavonoids are not without precedent. A diet of red clover can affect development and reproduction in livestock. And the New England Journal of Medicine documented breast development in prepubescent boys that was linked to the use of shampoos and balms containing lavender or tea tree oils containing flavonoids.

"Because flavonoid supplements are widely used, we need to do the research necessary to understand their effects, both desirable and undesirable, in consumers using these products. We shouldn't be taking this stuff blindly because, just like prescription medicines, there can be unanticipated consequences," Nordeen says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Commonly used herbicides seen as threat to endangered butterflies
2. Common North American frog identified as carrier of deadly amphibian disease
3. Researchers uncover molecular pathway through which common yeast becomes fungal pathogen
4. New research about facial recognition turns common wisdom on its head
5. Commonly used diabetes drug may help to prevent primary liver cancer
6. Loyola study debunks common myth that urine is sterile
7. Dental X-rays linked to common brain tumor
8. Women & Infants participating in study of treatment of common viral infection in pregnancy
9. Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers
10. Modest alcohol intake associated with less inflammation in patients with common liver disease
11. Sulphur and iron compounds common in old shipwrecks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... Safety, HealthCare, and Finance sectors announced today that Leaders in Community ... and deploy a community-based supportive services program to reduce recidivism in ... expanding its presence in the state. ... This new program, which is expected to commence ...
(Date:12/16/2016)... , Dec 16, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... The biometric ... grow at a CAGR of 14.06% from 2016 to 2021. The ... is projected to reach 854.8 Million by 2021. The growth of ...
Breaking Biology News(10 mins):
(Date:1/13/2017)... ... January 13, 2017 , ... ... demand that it has found among its diverse customer base. The latest entry ... in most brands electroporators including BTX and Bio-Rad. FireflySci is introducing three distinct ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... of performing routine electrochemical biosensing has increased dramatically. Primarily driven by the ... and quantification of various analytes in complex samples. , Screen-printed ...
(Date:1/12/2017)... 2017   Protein Sciences Corporation , a ... Flublok Influenza Vaccine ®, announced today that its ... safety results and induced strong neutralizing antibodies against ... is expected to advance into human clinical trials ... Institute of Technology in Immunobiologicals of the Oswaldo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase 1 clinical trial ... of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The ... percent of these heavily pretreated patients saw clinical benefit from the drug, with ...
Breaking Biology Technology: